Ajgal Z - Search Results

1

Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review.

Mignot F, Ajgal Z, Xu H, Geraud A, Chen JY, Mégnin-Chanet F, Kirova Y. Mignot F, et al. Among authors: ajgal z. Radiother Oncol. 2017 Aug;124(2):190-199. doi: 10.1016/j.radonc.2017.07.006. Epub 2017 Jul 24. Radiother Oncol. 2017. PMID: 28751231 Review.

2

Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.

Ajgal Z, de Percin S, Diéras V, Pierga JY, Campana F, Fourquet A, Kirova YM. Ajgal Z, et al. Cancer Radiother. 2017 Apr;21(2):114-118. doi: 10.1016/j.canrad.2016.10.002. Epub 2017 Mar 24. Cancer Radiother. 2017. PMID: 28347625

3

Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.

Lavaud P, Rousseau B, Ajgal Z, Arrondeau J, Huillard O, Alexandre J, Hulin A, Goldwasser F. Lavaud P, et al. Among authors: ajgal z. Breast Cancer Res Treat. 2016 May;157(1):191-2. doi: 10.1007/s10549-016-3798-8. Epub 2016 Apr 22. Breast Cancer Res Treat. 2016. PMID: 27106482 No abstract available.

4

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.

Velev M, Puszkiel A, Blanchet B, de Percin S, Delanoy N, Medioni J, Gervais C, Balakirouchenane D, Khoudour N, Pautier P, Leary A, Ajgal Z, Hirsch L, Goldwasser F, Alexandre J, Beinse G. Velev M, et al. Among authors: ajgal z. Pharmaceuticals (Basel). 2021 Aug 16;14(8):804. doi: 10.3390/ph14080804. Pharmaceuticals (Basel). 2021. PMID: 34451901 Free PMC article.

5

Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris.

Tlemsani C, Arrondeau J, De Percin S, Gataa I, Bretagne M, Ajgal Z, Huillard O, Wislez M, Coriat R, Alexandre J, Boudou-Rouquette P, Goldwasser F. Tlemsani C, et al. Among authors: ajgal z. Clin Med (Lond). 2021 Sep;21(5):e552-e555. doi: 10.7861/clinmed.2020-0666. Epub 2021 Aug 2. Clin Med (Lond). 2021. PMID: 34341004 Free PMC article.

6

Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.

Ajgal Z, Chapuis N, Emile G, Cessot A, Tigaud JM, Huillard O, Boudou-Rouquette P, Fontenay M, Goldwasser F, Alexandre J. Ajgal Z, et al. Cancer Chemother Pharmacol. 2015 Nov;76(5):1033-9. doi: 10.1007/s00280-015-2875-8. Epub 2015 Sep 29. Cancer Chemother Pharmacol. 2015. PMID: 26420236

7

Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial.

Hilmi M, Kamal M, Vacher S, Dupain C, Ibadioune S, Halladjian M, Sablin MP, Marret G, Ajgal ZC, Nijnikoff M, Salomon A, El Beaino Z, Servant N, Dureau S, Sokol H, Nicolle R, Le Tourneau C, Bieche I, Neuzillet C. Hilmi M, et al. Among authors: ajgal zc. Eur J Cancer. 2023 Apr;183:152-161. doi: 10.1016/j.ejca.2023.01.024. Epub 2023 Feb 8. Eur J Cancer. 2023. PMID: 36868056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page